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Background: Radiation therapy is commonly used as an adjunct to incomplete
surgical excision in dogs with mast cell tumors (MCT), but the optimal dose and frac-
tionation regimen have yet to be determined.
Hypothesis: We assessed outcomes (time to local recurrence, patient survival and
toxicity) of a large population of dogs with MCT that received adjunctive radiation
therapy.
Animals: Three hundred dogs with 302 MCT treated using adjunctive radiation
therapy.
Methods: Retrospective observational study. Clinical records of 4 veterinary radia-
tion centers were reviewed.
Results: Local recurrence rates were similar regardless of radiation protocol with
6.6% of patients developing recurrent cutaneous MCT at a median of 526 days. Local
recurrence rate was similar between high and low-risk MCT. Mast cell tumor related
death was reported in 19% of all dogs, with 13% of dogs with low-risk MCT dying of
their disease compared to 29% of dogs with high-risk MCT. No SC MCT (SCMCT)
recurred after radiation therapy and only 7% of dogs with SCMCT were reported to
have died of their disease. Mild late toxicity was common in both protocols and
severe late toxicity occurred in 1.9% of dogs many years after treatment.
Conclusions and Clinical Importance: Our study supports the use of adjunctive radia-
tion for the long-term control of incompletely or narrowly excised cutaneous and
SCMCT in dogs. More moderate dose and fractionation protocols may be appropriate
in the adjunctive treatment of low-risk MCT in dogs. Large multicenter prospective
Abbreviations: 95CI, 95% confidence interval; BED, biologically effective dose; cMCT, cutaneous mast cell tumor; CTV, clinical target volume; Hpf, high power field; ICRU, International
Commission on Radiation Units and Measurements; LN, lymph node; LTF, lost to follow-up; MCT, mast cell tumor; MCTSST, mast cell tumor specific survival time; MeV, megavoltage x-rays
(electrons); MI, mitotic index; MST, median survival time; MV, megavoltage x-rays (photons); NS, not specified; OAR, organs at risk; OST, overall survival time; PTV, planned target volume; RT,
radiation therapy; SCMCT, SC mast cell tumor; TKI, tyrosine kinase inhibitor; TLR, time to local recurrence; VRTOG, Veterinary Radiation Therapy Oncology Group
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studies are required to establish the optimal dose and fractionation for MCT of dif-
ferent risk categories.
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1 | INTRODUCTION
Mast cell tumors (MCT) account for up to 20% of cutaneous and SC
tumors in dogs and their presentation and clinical course vary among
individuals. Low and intermediate Patnaik and Kiupel low grade MCT
often are slow growing and relatively benign in clinical behavior, causing
problems by local invasion and ulceration rather than metastatic
spread.1-3 Histopathologic grade provides information regarding poten-
tial for local recurrence or metastasis, but factors such as size, clinical
appearance, location, proliferation or mutation markers, and clinical
stage also affect recurrence and metastasis.3-6 Some MCT are consid-
ered high risk including those with high expression of proliferation
markers or metastatic disease, despite low or intermediate grading.6
Wide surgical excision is the preferred treatment for localized
cutaneous or SC MCT (cMCT/SCMCT) and is curative when margins
are complete. However, complete excision is not always feasible in
areas in which spare skin or deep facial planes are lacking.3,7,8 Several
studies report high cure rates for low to intermediate grade MCT,
even when margins are incomplete,9-14 making the recommendation
for radiation challenging because some patients will be overtreated.
Adjunctive radiation is considered standard of care for incom-
pletely excised stage 1 and 2 cMCT when revision surgery is not pos-
sible.15-21 Control rates after adjunctive radiation of microscopic
cMCT range from 65% to 96%.15-21 Radiation causes acute (erythema,
desquamation, and ulceration) and late (leukotrichia, hyper-
pigmentation and cutaneous fibrosis) toxicity to normal tissues within
the treated field. More serious toxicities including vascular or lym-
phatic damage and subsequent lymphedema, osteoradionecrosis and
rarely, second tumor development may occur.22-24
Various adjunctive radiation protocols are reported for dogs with
MCT, with total doses between 48 and 57 Gy in daily or alternating
daily fractions of 3 to 4 Gy.15-21 The optimal total radiation dose or
regimen for adjuvant treatment of MCT in dogs is not yet established.
No specific report of the outcomes of dogs with SCMCT treated with
adjunctive radiation is available although this approach is commonly
employed.15-19 Biological effective dose (BED) is a concept that
defines radiation prescriptions with regard to their acute (Gy10) and
late (Gy3) effects on tumor and tissues and is more appropriately used
to describe protocols than is total dose.25 Radiosensitivity is
influenced by several factors and can vary widely across tumors, even
those of similar histopathogenesis. Mast cell tumor cell lines are of
medium radiosensitivity, compared with a range of other tumor cell
lines in dogs.26
We hypothesized that long-term control rates for dogs with
cMCT and SCMCT treated using adjunctive radiation would be similar
and independent of protocol. Objectives were to assess outcomes for
high dose fractionated protocols and lower dose coarse fractionated
regimens, to report tumor control in dogs with cMCT and SCMCT,
and high-risk vs low-risk MCT and to assess the prevalence and sever-
ity of acute and late radiation toxicity.
2 | MATERIALS AND METHODS
2.1 | Study design
Ours was a retrospective observational multicenter study. Dogs were
enrolled from 4 UK veterinary radiation centers and the study was
approved by each center's ethical committee. A standard spreadsheet
(MSOffice Excel v365) and information sheet quantifying methodol-
ogy for data collection were provided. Patients treated from 1 January
2008 until 31 December 2016 were included. Data were collected
between September 2017 and June 2018.
Case records of dogs that received adjunctive radiotherapy (RT) for
cMCT/SCMCT were retrospectively reviewed. Inclusion criteria were
histopathological diagnosis of cMCT/SCMCT and adjunctive
RT. Primary and recurrent MCT were included, as were MCT with
incomplete or narrow histopathological margins and those with
reported clear histopathological margins but clinical uncertainty. Exclu-
sion criteria were macroscopic MCT, macroscopic lymph node (LN)
metastasis (palpable) or mucosal MCT.
Data collected included signalment, MCT position (SC vs cutane-
ous) and location (distal or proximal limbs, thoracic or abdominal wall,
head, muzzle, dorsum, inguinal, perineal, other), histopathological grad-
ing, mitotic index (MI), Ki67 score when performed, clinical staging and
any treatment before, during or after surgery or radiation therapy (eg,
prednisolone, chemotherapy tyrosine kinase inhibitors), time from sur-
gery to first radiation treatment (defined as first surgery in the case of
recurrent tumors). Tumor size was not available in most patients as they
presented to the radiation center after surgery in a local practice.
Both Patnaik27 and Kiupel28 gradings were recorded if available
for cMCT. Histopathology reports were reviewed by a board-certified
oncologist when available. Incomplete excision was considered if it
was directly reported or tumor cells were seen at the edges of excised
tissue. Narrow excision was defined histologically as ≤1 mm margin,
vs complete excision as >1 mm.29 SCMCT was defined as tumor con-
fined to the subcutis.
High-risk MCT was defined as any tumor of high Patnaik or
Kiupel grade, MI ≥5/10 per high power field (hpf) for cMCT,30
MI > 4/10 for SCMCT,31 Ki67 above threshold,4,32-34 pathologist
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description of the MCT as high grade, and clinical stage 2 or 3, even if
histopathologic description did not include MI or Ki67.
The MCT were considered low risk if defined as any of the
following: low-grade Kiupel or low to intermediate Patnaik grade, MI
<5 for cMCT or <4 for SCMCT, Ki67 below threshold and clinical
stage was 1 or not recorded within these histopathological and immu-
nohistochemical features.
The MCT were considered of unknown risk if the histopathology
report did not provide a grade, or if grade was intermediate with no
MI or Ki67 available. Tumor stage was determined by the modified
World Health Organization (WHO) staging system (Table 1).
Follow-up data were collected from medical records, or by email
or telephone follow-up with referring veterinarians. Follow-up data
included recorded radiation toxicity, recurrence, metastasis, or new
MCT and the dates observed, the date the animal was last seen alive
and healthy (no MCT) or was euthanized or died, and the cause of
death where known.
Dogs were treated with different protocols and linear accelera-
tors (Table 2).
Treatments were grouped into:
1. Coarse fractionated total dose ≤40 Gy (≥5 Gy fractions))
2. Fractionated total dose >40 Gy (daily, or Monday, Wednesday, Fri-
day ≤4 Gy fractions)
Treatment data collected included total radiation doses, fraction
numbers, field sizes in cm (converted to equivalent square by the
TABLE 1 World Health Organization (WHO) staging system
Stage Criteria
I One tumor confined to dermis (or subcutis for SC mast
cell tumor) without regional LN involvement
II One tumor confined to dermis with regional LN
involvementa
III Multiple dermal tumors, large infiltrating tumors with or
without regional LN involvement
IV Any tumor with distant metastasis including blood or
bone marrow
aRegional LN involvement can be cytological or histopathological diagnosis
of metastasis.








prescribing Standard photon prescribing
A (36 MCT) Varian Clinac
23EX
7 4  8 Gy weekly (32 Gy)
1 5  6 Gy weekly (30 Gy)
2 6  6 Gy biweekly (36 Gy)
(BED = 57.6 Gy10,
117.3 Gy3)
23 16  3 Gy (48 Gy)
1 14  3.5 Gy (49 Gy)
1 15  3.2 Gy (48 Gy)
1 15  2.7 Gy (40.5 Gy)
(BED = 60.1-63.4 Gy10,
90-99.2 Gy3)
100% dose to the
skin using
appropriate bolus
Single field—100% dose to the
skin using appropriate bolus
Parallel opposed fields—100%
dose to the midpoint using
appropriate bolus
B (28 MCT) Siemens Oncor
Impression Plus
20 (71%) 8  5 Gy biweekly
5 Gy (40 Gy)
(BED = 60 Gy10,
106.6 Gy3)
7 (25%) 12  4 Gy MWF
(48 Gy)
1 (4%) 11  4 Gy (44 Gy)
(BED = 67.2 Gy10,
112 Gy3)




C (102 MCT) Varian Clinac
DMX 6100
93 (91%) 4  8 Gy weekly
(32 Gy)
3 (3%) 4  7.5 Gy weekly
(30 Gy)
3 (3%) 3  8 Gy/1  7 Gy
weekly (31 Gy)
3 (3%) 3  8 Gy/1  7.5 Gy
(31.5 Gy)
(BED = 52.5-68.4 Gy10,
105-130 Gy3)




D (136 MCT) Varian Clinac
600C
67 (49%) 4  8 Gy weekly
(32 Gy) weekly
12 (9%) 4  9 Gy weekly
(36 Gy)
(BED = 57.6-68.4 Gy10,
117-144 Gy3)
47 (34%) 16  3 Gy
(48 Gy)
1 (0.7%) 16  3.1 Gy
(49 Gy)
1 (0.7%) 17  3 Gy
(51 Gy)
1 (0.7%) 18  3 Gy
(54 Gy)
7 (5%) 15  3 Gy (45 Gy)
(BED = 58.5-70 Gy10,
90-108 Gy3)
N/A As above
Note: The range of biologically effective dose is displayed in bold.
Abbreviations: BED, biologically effective dose; MCT, mast cell tumors; N/A, not applicable.
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formula 2  X  Y/ (X + Y), number and arrangement of fields, type of
energy (photons vs electrons), energy used, bolus or blocks used, man-
ual or computer plan, margins around clinical target volume (CTV)
defined as surgical scar or tumor bed.
Radiation toxicity was scored retrospectively by Veterinary Radia-
tion Therapy Oncology Group (VRTOG) criteria.22
2.2 | Statistical analysis
A power study estimated 90% tumor control in the fractionated
group based on previous studies and 85% in the hypo-
fractionated groups based on first principles and clinical experi-
ence. Using 80% chance of detecting a difference with 5%
significance >1000 dogs were required to reach statistical power,
which was higher than the number of available cases. Hence, we
did not attempt statistical comparison of outcomes between
treatment groups.
Kaplan-Meier product estimates were used to compare over-
all survival time (OST), MCT specific survival time (MCTSST) and
time to local recurrence (TLR) for the group and TLR and MCSST
between risk groups. Time to local recurrence was calculated
from the date RT started to the date the tumor recurred. Dogs
with no recurrence, that died from other causes, or those lost to
follow-up (LTF) were censored at the last date seen alive and
MCT free.
The MCTSST was calculated for dogs that died from con-
firmed or suspected local or systemic MCT. Death was considered
MCT related if signs could be attributed to MCT, even if
unconfirmed. Dogs alive at the end of the study period, LTF, or
that died from other causes while MCT free were censored on the
date last seen.
Descriptive statistics were performed across groups to
assess distribution of characteristics and to compare toxicity by
Chi-squared and Kruskal-Wallis tests. Significance was set
at P = .05.
3 | RESULTS
3.1 | Study population
Three hundred dogs were included: 154 female neutered, 109 male
neutered, 17 female, and 20 male intact. Median age was 8 years
(range, 1-16). Breeds are summarized in the Supporting Information.
Three hundred and two MCT were treated in 300 dogs. Center A
contributed 36 MCT in 35 dogs, center B 28 MCT in 28 dogs, center
C 102 MCT in 101 dogs and center D 136 MCT in 136 dogs. Most
MCT were appendicular (243/302, 80%) with 184 (76%) on the distal
limb and 59 (24%) on the proximal limb. There were 19 (6%) on the
muzzle, 15 (4.9%) on the head, 5 (1.6%) on the thoracic wall, 5 (1.6%)
on the dorsum, 3 (1%) on the abdominal wall, 1 (0.3%) inguinal, and
4 (1.3%) perineal. Seven (2.3%) were classified as other (2 tail base,
1 prepuce, 1 umbilical, 3 not recorded).
There were 244 (81%) cMCT, 55 (18.2%) SCMCT, and 3 (1%) not
specified (NS), which were either cutaneous or SC on review of histol-
ogy. Five (1.6%) MCT had clear margins of excision (4 [80%] low risk,
1 [20%] high risk), 29 (9.6%) narrow margins (7 [24%] high risk,
21 [72%] low risk, 1 [3%] unknown risk), 265 (87.7%) had incomplete
margins (88 [33%] high risk, 163 [62%] low risk, 14 [5%] unknown
risk), in 3 (1%) MCT margins were recorded as not known (2 [66%]
unknown risk, 1 [33%] low risk).
Not all MCT had Patnaik/Kiupel grading reported. Of 238/244
cMCT (97.5%) that had a Patnaik grade, 19 (7.9%) were low grade,
TABLE 3 Mast cell tumors (MCT) results populations
Coarse fractionated group Fractionated group
P value
(significance ≤.05)
Patient median age (y) 8 (range, 1-13.7) 8 (range, 2-13)
Total number MCT 211 91
Cutaneous 165 (78%) 79 (87%) .57
SC 43 (20%) 12 (13.2%) .49
Not recorded 3 (1.4%) 0 NA
Stage 1 150 (71%) 68 (75%) .79
Stage 2 25 (12%) 17 (19%) .17
Stage 3 4 (1.8%) 6 (6.6%) .04
Stage not recorded 32 (15%) 0 NA
Received any chemotherapy 46 (22%) 25 (27%) .4
Incomplete margins 186 (61.6%) 83 (27.4%) .85
Complete margins 4 (1.3%) 1 (0.3%) .62
Narrow margins 18 (5.9%) 7 (2.3%) .82
Not recorded margins 3 (1%) 0 NA
Median time from surgery to radiation therapy (d) 32 (range, 4-277) 36 (range, 9-173) .09
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207 (87%) intermediate grade, and 12 (5%) high grade. Of 231/244
(95%) that had Kiupel grading, 206 (89%) were low grade, and
25 (11%) high grade. When grouped for high-risk characteristics
96 (32%) MCT (83 cMCT and 13 SCMCT) were included, 189 (63%;
149 [79%] cMCT and 40 [21%] SCMCT) MCT were included in the
low-risk group and 17 (5.6%; 12 cMCT [71%], 2 [12%] SCMCT, 3 NS
[17.6%]) in the unknown risk group.
Two hundred and eighteen (72%) MCT were recorded as clinical
stage I, 42 (14%) stage II, 10 (3%) stage III, and stage was not available
for 32 MCT (11%). One of 2 dogs with 2 MCT was considered stage
III and, in the other, stage was not recorded. Stage was distributed
equally across treatment groups except stage 3 where more received
fractionated protocols (Table 3).
3.2 | Radiation treatment
Most primary field treatments (275/302 [91%]) were single beam, 22/
302 (7.4%) were parallel opposed beams and in 5/302 (1.6%) beam
arrangements were not recorded. Only 1 MCT was treated using a
computer-generated 3-dimensional plan, the remainder were manually
planned. Tissue equivalent bolus 5 to 10 mm (Superflab, CIVCO,
Kalona, Iowa) was used in all cases. Treatment was prescribed to the
95% to 100% isodose line depending on energy used for single field
electron treatments, to maximum depth (dMax) for single beam pho-
ton fields and to the midpoint of the limb for parallel opposed photon
fields.
Because most patients were presented after surgery in the micro-
scopic setting, the surgical scar was used to estimate clinical target
volume (CTV). Commonly 2 to 3 cm combined CTV and planned treat-
ment volume (PTV) margins were applied proximally, distally, and
when possible, laterally to include the scar. The retrospective nature
of the study did not permit more detailed assessment. Twenty-seven
dogs (9%; 26 limb MCT, 1 head MCT) had the regional LN treated
with radiation at the clinician's discretion, and prophylactically in all
cases. All LN were irradiated in situ. Field size to the regional LN when
not included in the primary field was recorded in 16 (60%) patients
and the remaining 11 (40%) LN were included in the primary field.
Median equivalent square field size was available for 281 (93%)
treated primary fields and was 10.66 cm2 (range, 2.66-18.75 cm2).
Median LN field size was 6.88 cm2 (range, 4-10 cm2).
A total of 179/302 (59%) MCT were treated with 6 MV photons,
and the remainder with electrons: 99 (33%) primary fields were
treated with 6 MeV electrons, 6 (2%) with 8 MeV electrons, 8 (3%)
with 9 MeV electrons, 5 (2%) with 10 MeV electrons, 3 (1%) with
12 MeV electrons, 1 (1%) with 15 MeV electrons, and in 1 field elec-
tron energy was not recorded. In patients in which the energy to the
node was recorded 10/27(37%) received 6 MV photons and 4/27
(15%) 6 MeV, 1/27 (3.7%) 8 MeV, and 3/27 (1.1%) 9 MeV electrons.
One dog (3.7%) received primary site 6 MeV, LN 9 MeV, and
2 (7.4%) dogs received 9 MeV to the primary site and 6 MeV to
the LN.
The use of blocks was recorded in 97 (32%) treatments, not
reported in 63 (21%) treatments and 142 (47%) treatments were per-
formed without blocks.
Two hundred and eleven (70%) MCT received coarse and
91 (30%) conventionally-fractionated treatments. Characteristics for
each group are summarized in Table 3.
3.3 | Chemotherapy
Seventy-one dogs received chemotherapy/tyrosine kinase inhibitor
(TKI) treatment (Table 4). Of dogs receiving any chemotherapy,
38 (53%) stage I, 23 (32%) were stage II, 3 (4%) stage III and in 7 (10%)
stage was not recorded. Forty (56%) of the dogs that received chemo-
therapy were high risk, 24 (34%) low risk, and 7 (10%) unknown risk.
Thirteen of 71 (18%) dogs that received combination RT and chemo-
therapy received RT to the local LN. Dose reductions were performed
if toxicity was observed at the maximumly tolerated dose.
Median follow-up time for the entire population was 975 days
(range, 20-3610 days).

























N/A 2 VBL 2 VBL, 2 CCNU, 1
CHL, 2 OTH









VBL, 1 OTH, 1
CCNU/OTH
N/A 6 VBL, 2 TOC, 2
MAS/OTH, 1 MAS,
3 CCNU, 1 CCNU/
VBL, 1 CCNU/
TOC, 1 OTH




20 dogs 4 VBL, 1
VBL/CCNU
1 CCNU, 1 MAS,
1 OTH
N/A 1 CHL, 2 VBL, 4
CCNU
3 VBL, 1 CCNU 1 VBL
Total 71 14 12 0 26 12 7
Abbreviations: CCNU, lomustine; MAS, masitinib; OTH, other; TOC, toceranib; VBL, vinblastine.
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3.4 | Outcomes
Twenty of 302 (6.6%) tumors recurred locally with a median TLR
of 526 days (range, 21-2929 days; Figure 1). All were cMCT; no
SCMCT recurred. Six of 99 MCT treated with photons (6%) and
14/179 MCT treated with electrons recurred (8%; P = .61). Of 20
recurrent tumors, 6 (30%) had the local LN treated, 5/6 (83%)
were high-risk MCT, 2/6 (33%) had documented LN metastasis
after radiation. Thirteen tumors recurred after coarse fractionated
protocols (6.2%) and 7 recurred after conventionally fractionated
radiation protocols (7.7%). Dogs with tumor recurrence had a
median OST of 972 days (range, 244-3037 days).
For 7/91 (7.7%) MCT recurrent after conventionally fraction-
ated RT, 2 (29%) were high risk and 5/7 (71%) low risk. Surgery
to radiation time was 173 (date of recurrence not recorded)
and 31 days (recurrence, 515 days) for the high-risk recurrent
tumors. The first patient received chemotherapy with lomustine
and then toceranib and survived 233 days. The other survived
678 days.
The low risk recurrent MCTs had a median time from surgery to
radiation of 40 days (range, 33-55 days) for the 4 patients in which
this time was recorded. Median time to recurrence for low-risk
dogs that received fractionated radiation was 462 days (range,
380-669 days). Five (71%), (3 [60%] systemic and 2 [40%] local
F IGURE 1 Time to local recurrence
for 18 of the 20 dogs, in which the date
of recurrence was recorded
F IGURE 2 Overall survival time for
the whole cohort. Censored dogs were
alive or lost to follow-up
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disease) dogs died and 2 [29%] were censored, MCTSST was 673 days
(range, 400-1122 days).
For 13/211 (6%) MCT that recurred after coarse fractionated radia-
tion, 5 (38.4%) were high risk, 7 (54%) were low risk and 1 (7.6%) tumor
was of unknown risk. One high risk, high grade and recurrent MCT which
had a long time (168 days) from first surgery to second surgery and sub-
sequent prompt radiation recurred at the last radiation fraction (21 days)
and received masitinib during and after radiation. Four other high-risk
tumors had a median time from surgery to RT of 21 days (range,
12-277 days), recurred at a median of 164 days (range, 110-576 days)
and 2 (50%) received chemotherapy (vinblastine and other drugs). Time
of recurrence was recorded for 6/7 (86%) low-risk MCT with a median
time from surgery to RT of 39 days (range, 19-233 days) and median
TLR was 1224 days (range, 537-2929 days). The unknown risk MCT
F IGURE 3 (A) Mast cell tumor specific
survival time (MCT SST), censored dogs were
alive, lost to follow-up or dead of non MCT
related causes. (B) MCT SST by risk, censored
dogs were alive, lost to follow-up or dead of non
MCT related causes. (C) MCT SST by treatment
protocol
MASON ET AL. 7
recurred 64 days after radiation. Three (43%) of the low-risk tumor
patients also received chemotherapy. Ten (77%) of these dogs were dead
at the study end, with 8/10 (80%) considered to have died of MCT (5 sys-
temic and 3 local disease). Seven of 96 (7%) high risk, 12/189 (6%) low
risk, and 1/17 (6%) unknown risk MCT recurred.
Fifty-nine of 300 (19.6%) dogs died of MCT (11 [19%] local dis-
ease, 48 [81%] systemic disease), and 77 (26%) dogs died of non-MCT
related causes by the end of the study. Mean OST was 1830 days
(95% confidence interval [95CI]: 1679-1982 days), and median OST
was 1894 (95CI: 1716-2071 days; Figure 2).
Mean MCTSST was 2652 days (95CI: 2433-2871 days). Median
MCTSST was not reached (Figure 3A). For dogs dead of MCT, MST
was 486 days (range, 24-3037 days). Twenty-four of 59 (40.6%) were
in the low-risk group, 30/59 (51%) in the high-risk group and 5/59 of
unknown risk (8.4%). Twenty-four of 187 (13%) of low-risk MCT dogs
were considered to have died of their disease compared with 30/96
(31%) high risk and 5/17 (29%) unknown risk dogs. The MCTSST by
risk is shown in Figure 3B, and the protocol in Figure 3C.
Fifty-five dogs had SCMCT with median time between surgery
and RT of 34 days (range, 8-152 days). Seven (12.4%) were high risk,
46/55 (84%) were low risk and 2/55 (3.6%) were of unknown risk.
None had recurrent disease, and median follow-up was 987 days
(range, 21-2444 days). Four of 55 patients (7.2%) were considered
dead of MCT, 12/55 (22%) dead of other causes, 35/55 (64%) were
alive and disease-free at the end of the study, and 3/55 (5.4%) were
lost to follow-up. Eleven (20%) dogs received fractionated radiation
and 44/55 (80%) received coarse fractionated radiation. Eight dogs
received concurrent chemotherapy, 4/8 (50%) high risk (2/4, MI > 4,
Ki67 > 1.8, 1/4, stage II), 3/8 (38%) low risk and 1/8 (12.5%) of
unknown risk.
The 4 SCMCT dogs dead of MCT received coarse fractionated
radiation. One had high Ki67, was treated with adjunctive vinblastine
and was euthanized for MCT after 318 days. Three had low risk fea-
tures. One developed presumed MCT metastasis in the axilla and was
euthanized after 1121 days. The other 2 dogs were euthanized at
476 and 1054 days with no confirmed reason recorded. Thirty-five
dogs (12%) developed distant de novo MCT after radiation therapy.
No additional data regarding these tumors were collected.
3.5 | Toxicity
Toxicity assessment was not standardized and was assessed at vari-
able times, typically at the end of and 2 weeks after completion of RT
for acute toxicity. Late toxicity was assessed at the time of follow-up
if the dog was not presented specifically before then. One-hundred
and eighty-four of 300 (61%) dogs were reported to have had acute
radiation-associated toxicity (Table 5) of higher grade in the fraction-
ated group than in the coarse fractionated group (36% vs 10.2%,
G2/G3) which was significant (P = .02). One hundred and eight of
300 (36%) dogs were reported to have had late radiation toxicity dis-
tributed similarly across treatment groups (Table 6). Six of 302 dogs or
sites (1.9%) had grade 3 late toxicity reported after radiation treat-
ment for MCT (Table 6).
4 | DISCUSSION
We confirmed that adjunctive radiation can result in good outcomes
in dogs with incomplete or narrowly but completely excised MCT, and
TABLE 6 Acute radiation-related
toxicity by radiotherapy protocol and
VRTOG grade
Coarse fractionated (209 dogs)a
Fractionated (91
dogs)a
None evident 88 (42%) 48 (53%)
VRTOG grade 1 66 (skin) (32%) 35 (skin) (38%)
VRTOG grade 2 1 (bone) (0.4%) 0





72 (34%) 36 (40%)
Not recorded 51 (24%) 7 (8%)
Follow-up time (days) 991 (21-3610) 929 (42-3399)
Abbreviation: VRTOG, Veterinary Radiation Therapy Oncology Group.
aDogs may have >1 toxicity reported.
TABLE 5 Acute radiation-related toxicity by radiotherapy





None evident 98 (52%) 18 (20%)








5 (skin) (2.6%) 21 (skin) (23%)
Not recorded 23 2
Abbreviation: VRTOG, Veterinary Radiation Therapy Oncology Group.
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assessed a large population of patients that received relatively stan-
dardized treatment protocols with long follow-up. Seventy-five per-
cent of recurrences occurred within 2 years of treatment in our
population, but 25% of patients developed recurrence between 2 and
8 years after treatment.
Our recurrence rate of 6.6% is lower than that of many previous
reports,15-21 including the up to 36% reported for incompletely
excised MCT treated with surgery alone.9,12,35 Ours is the first report
of outcomes for SCMCT treated by adjunctive radiation and suggests
that the combination of surgery and RT results in excellent local con-
trol of SCMCT. Radiation toxicity was similar to that previously
reported with a low rate of severe late toxicity. 36
Mast cell tumor recurrence after incomplete surgical excision in
small numbers of dogs has reported rates of 4% to 36%9-12,29,35
Patients that had high grade MCT and MCT with high proliferation
indices are more likely to experience recurence.9,12 Local recurrence
rates for SCMCT are 7% to 8% overall,31,37 (ie, 12% in dogs with
incompletely excised tumors and 2% in dogs with complete exci-
sion).31 Our local control rates of 93.4% to 100% for cMCT and
SCMCT respectively are consistent with clinical benefit for the popu-
lation over surgery alone, but some individual patients, especially
those with low-risk MCT, may have been overtreated given the low
rate of local recurrence reported with surgery. It is also likely however
that a substantial number of dogs referred for radiation have clinically
or histopathologically more aggressive MCT than those having surgery
alone, but no studies are available to substantiate this suspicion.
Future research should focus on determining prognostic factors for
MCT recurrence to help determine which cases would benefit from
adjunctive radiation.
Considering high risk tumors as a separate group, local recurrence
rate after adjunctive RT was similar to that of low and unknown risk
tumors, although not statistically assessed because of the low number
of recurrences and variation in grade, risk, and margin status. More
dogs with high-risk tumors (31%) died of MCT disease, likely because
of metastasis, despite chemotherapy in many cases, compared with
low-risk dogs (13%). This observation was not statistically assessed
because of the number of unknown risk dogs included in the study.
We acknowledge that MCT specific death was not confirmed in most
patients because of the retrospective nature of the study, and lack of
necropsy, meaning that dogs that died of other causes may have been
included. High-risk MCT in our study subjectively recurred sooner
than did low-risk MCT. Low recurrence rate and different radiation
protocols limited interpretation of this suspicion but time to recur-
rence may reflect cell proliferation and specific cellular responses to
radiation.
Our good control rates may in part be related to the inclusion of
55 (18%) SCMCT in the study, which have lower recurrence rates
than do cMCT.31 However, a similar situation was likely to have
occurred in historical reports on the role of adjunctive RT, most of
which were undertaken before the separate categorization of
SCMCT.38 A rate of 7% SCMCT related death in our population is
consistent with previous findings.31,38,39
We wanted to compare local control rates for MCT treated with
higher dose conventional fractionated regimens with those treated
with lower dose coarse fractionated regimens, but the number of
cases available was not high enough to achieve statistical significance.
The inclusion of tumors of mixed grade, different clinical stages and
nonstandardized radiation protocols contributed further to the lack of
statistical power. Recurrence rates however were subjectively similar
between protocols, which suggests that moderate dose radiation pro-
tocols may be adequate for local control of most MCT in dogs.
A previous study reported 10% recurrence in 20 dogs that
received 48 to 60 Gy in daily or alternate day fractions.19 Considering
that 93% were Patnaik low or intermediate grade and that other stud-
ies with definitive intent protocols reported similar recurrence rates
of 7% to 16%, our results support the hypothesis that total radiation
dose or fractionation may be less important than, for example, tumor-
related factors in determining outcome.
Fewer than 10% of dogs in our population had the local LN
irradiated despite 42 dogs being in stage 2. Interpretation of stage
is limited because of the retrospective nature of the study, with
some dogs having had cytological suspicion of LN metastasis and
others having had the LN extirpated. Unfortunately, many clinical
records were incomplete regarding LN management. Almost all of
the LN in our study were treated with electrons of variable energy.
Because most were limb MCT, it is likely that the LN was superficial
and palpable, and that dosimetry was appropriate in these cases,
but this aspect was impossible to quantify from the clinical records.
Additionally, LN treated were not documented, and may not have
represented the draining LN in all cases. Prophylactic LN radiation
remains controversial with many historical studies reporting it as an
alternative to surgical excision, but recent evidence suggests that
LN micrometastasis is less prognostic than previously thought, with
many patients experiencing long survivals, particularly if
lymphadenectomy is included in the treatment, which is now rec-
ommended.40,41 One study that evaluated prophylactic radiation of
regional LNs in 6 dogs with MCT reported improved locoregional
control42, but evidence for surgical expiration currently is more
strongly supported.41,43
Radiation therapy should commence as soon as possible after
wound healing to allow the best chance of tumor control. Median
time from surgery to radiation in our population was 32 days in the
coarse fractionated group and 36 days in the fractionated group, lon-
ger than normal wound healing. This delay likely reflects the fact that
radiation is often a late treatment consideration after incomplete exci-
sion is confirmed and delays in organizing referral have occurred.
Some dogs did not receive radiation for a prolonged time after surgery
because of owner-related factors.
The median time from surgery to radiation in patients with MCT
that recurred in our study was 39.5 days, which is slightly longer than
the median for the population overall, but this time was not statisti-
cally assessed because of the low numbers of recurrences. The
2 patients with rapidly recurring MCT after long periods of time from
surgery to the start of RT had recurrent tumors that were debulked
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again before RT. It is likely these patients would have a less favorable
response to RT, given demonstratable clinically aggressive behavior of
their tumors. It would have been preferable to clarify the number of
patients treated with recurrent vs initial MCT, because this difference
also may influence the success of RT. Unfortunately, clinical records
from the referring veterinarians were often incomplete with regard to
this factor. Previous studies however also included mixed populations
of patients having initial and recurrent MCT irradiated, but unfortu-
nately not specifying the numbers that were recurrent.15-21
The optimal margin of healthy tissue to be included in the radia-
tion field has not been established for dogs with MCT, and although
combined CTV/PTV margins of 2 to 3 cm were common it was not
possible to establish whether these were from the macroscopic tumor
margin or the surgical scar, because patients were commonly referred
for radiation by primary care veterinarians after surgery without
tumor measurements. In the latter situation topographical omission of
tumor tissue is possible. Most patients referred for radiation had sur-
gery at the local practice and in most cases tumor measurements were
not available. With improved veterinarian education and more access
to digital photography, all patients should have presurgical photo-
graphs and measurements recorded to assist in accurate treatment
planning and to minimize risk of missing affected tissue.
Not all dogs in our study had full staging and thus tumor stage
may have been underestimated, but the low number of patients that
died of mast cell disease makes this possibility unlikely. It is unlikely
given the poor prognosis associated with stage 4 MCT that clinicians
would recommend RT for these patients.44
One consideration in offering adjunctive radiation is the chance
of the patient developing de novo MCT in the future, estimated as up
to 21%.3 In our study, a rate of 12% was within the expected range.
The radiation prescription also should consider organs at risk
(OAR), total dose required for tumor control and dose fractionation.25
The biologically equivalent dose should be calculated and applied to
the individual situation and OAR.25 In our study, most tumors were
appendicular, where the OAR consists of skin, bone, and vasculature.
Acute toxicity was more severe in the fractionated group than in
the coarse fractionated group, with 36% of patients in the former
group developing VRTOG grade 2/3 dermatitis or desquamation or
both. This adverse effect takes a median of 25 days to resolve,45
often requires analgesia or other topical treatment and can be dis-
tressing for the dogs and their owners. Additionally, severe acute tox-
icity can lead to consequential late toxicity, none of which was seen in
our population although the follow-up may have been too short. A
high percentage of dogs in our study were reported as having no tox-
icity compared to the patients in a previous study.36 This difference
may reflect less robust reporting, less frequent assessment of toxicity,
or genuine differences in population. In centers C and D, it is uncom-
mon for radiation patients to receive concurrent prednisolone, com-
pared to the group reported previously that all received adjunctive
glucocorticoids.36
Late toxicity in this population was similar between the standard
and coarse fractionated groups, mainly mild and comparable to that
previously reported15-21 consisting mainly of alopecia, leukotrichia
and cutaneous fibrosis. Substantial late toxicity (considered life
changing) was reported in 1.9% dogs and occurred 910 to 2600 days
after radiation. All of the critical late effects were associated with
coarse fractionated protocols with high BEDGy3 values, some of
which are no longer used in the United Kingdom. Although 3 dogs
that received 32 Gy in 4 weekly fractions developed severe compli-
cations, these all occurred >1800 days after RT. Because it was the
most common protocol used in the study (63% of dogs) and dogs that
received this protocol often were more commonly treated in the ear-
lier years of the study, it is unclear whether these complications were
a direct consequence of coarse fractionation, or if they reflect longer
follow-up. The development of second tumors is consistent with pre-
vious reports of outcomes 2 to 6 years postradiation,23,24 with
osteoradionecrosis occurring in 2 dogs within the reported timeframe
of 1.2 to 8.7 years.
The observed low rate of 1.9% for severe late complications may
reflect the high percentage of dogs treated using electrons in our pop-
ulation (all affected dogs received photons). Additional studies and
longer follow-up are required to assess the incidence of late complica-
tions. Consideration should be given to the age of the patient at the
time of radiation, and the lifetime risk compared with the benefit of
tumor control.
Our study had some limitations associated with its retrospective
design. Because patients were commonly presented to the radiation
center having already had surgery, tumor size, an important prognos-
tic indicator, was not available. Considering radiation field size and
mainly appendicular location, however, our population is comparable
with those of previous studies and reflects clinical practice.15-21 Clini-
cal records and staging were not always complete and histopathology
specimens were not reassessed. Given the large number of patients
and low number of recurrences however these limitations are unlikely
to have had substantial impact on the results. Recurrence of MCT,
new MCT occurrence and MCT-related death may be under reported
and MCT related death may be over-, or under-estimated because no
dogs were known to have had necroscopy performed. Some patients
received adjunctive, nonstandardized chemotherapy, which may have
contributed to improved systemic control. Toxicity also may have
been underreported. Given the retrospective nature of the study and
format of the clinical records, it was impossible to apply International
Commission on Radiation Units and Measurements (ICRU) reporting
guidelines.46
We have shown that local control of MCT in dogs is very good
after combined surgical excision and radiation therapy, even for dogs
with high-risk MCT. Dogs with SCMCT achieved excellent local con-
trol using this regimen. Mast cell tumor related death did occur, and
was attributed more to confirmed or suspected metastatic disease
rather than local failure and more commonly in high-risk MCT cases,
but most patients still experienced good survival times after radiation.
Late radiation toxicity was common and similar between protocols.
Clinically relevant late toxicity was uncommon.
We propose, based on these results, that more moderate dose
and fractionation protocols may be appropriate in the adjunctive
treatment of MCT in dogs. Radiation oncologists should work
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together to prospectively evaluate an appropriate regimen, based on
current evidence and biologically equivalent dose calculations.
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